Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: the ESTANVO Randomized Trial

Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS

开始日期2025-03-24

申办/合作机构

Centre FranÃ§ois Baclesse

NCT06798922

/ Not yet recruiting临床3期IIT

Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers: a De-escalation Randomized Phase III Trial

Patients with oral cavity cancer treated by reconstructive surgery with a flap.
Patients will be treated in the study for :
* Experimental arm: Post-operative radiotherapy with flap sparing
* Control arm: Standard post-operative radiotherapy without flap sparing (current practice) Radiotherapy by IMRT using photons or proton therapy (IMPT)

开始日期2025-03-01

申办/合作机构

Centre FranÃ§ois Baclesse

NCT06792721

/ Not yet recruitingN/AIIT

EVALUATION of CANCER RISK by MEASUREMENT of CIRCULATING MUTATIONAL BURDEN in CARRIERS of a GENETIC PREDISPOSITION

Cancer-free women with a hereditary predisposition to breast and/or ovarian cancer

开始日期2025-02-15

申办/合作机构

Centre FranÃ§ois Baclesse

100 项与 Centre FranÃ§ois Baclesse 相关的临床结果

登录后查看更多信息

0 项与 Centre FranÃ§ois Baclesse 相关的专利（医药）

登录后查看更多信息

1,726

项与 Centre FranÃ§ois Baclesse 相关的文献（医药）

2025-07-01·Critical Reviews in Oncology/Hematology

Optimizing imaging modalities for sarcoma subtypes in radiation therapy: State of the art

Review

作者: Rozenblum, Laura ; Jouglar, Emmanuel ; Khurana, Sakshi ; Thariat, Juliette ; El Fakhri, Georges ; Mahe, Mathilde ; El Ayachi, Radouane ; Beddok, Arnaud ; Helfre, Sylvie ; Najem, Elie ; Dercle, Laurent ; Mammar, Hamid ; Kaur, Harleen

The choice of imaging modalities is essential in sarcoma management, as different techniques provide complementary information depending on tumor subtype and anatomical location. This narrative review examines the role of imaging in sarcoma characterization and treatment planning, particularly in the context of radiation therapy (RT). Magnetic resonance imaging (MRI) provides superior soft tissue contrast, enabling detailed assessment of tumor extent and peritumoral involvement. Computed tomography (CT) is particularly valuable for detecting osseous involvement, periosteal reactions, and calcifications, complementing MRI in sarcomas involving bone or calcified lesions. The combination of MRI and CT enhances tumor delineation, particularly for complex sites such as retroperitoneal and uterine sarcomas, where spatial relationships with adjacent organs are critical. In vascularized sarcomas, such as alveolar soft-part sarcomas, the integration of MRI with CT or MR angiography facilitates accurate mapping of tumor margins. Positron emission tomography with [18 F]-fluorodeoxyglucose ([18 F]-FDG PET) provides functional insights, identifying metabolically active regions within tumors to guide dose escalation. Although its role in routine staging is limited, [18 F]-FDG PET and emerging PET tracers offer promise for refining RT planning. Advances in artificial intelligence further enhance imaging precision, enabling more accurate contouring and treatment optimization. This review highlights how the integration of imaging modalities, tailored to specific sarcoma subtypes, supports precise RT delivery while minimizing damage to surrounding tissues. These strategies underline the importance of multidisciplinary approaches in improving sarcoma management and outcomes through multi-image-based RT planning.

2025-07-01·Environmental Research

Associations between agricultural use of pyrethroid insecticides and asthma: AGRICAN cohort results

Article

作者: Baldi, Isabelle ; Lebailly, Pierre ; Douwes, Jeroen ; de Graaf, Lucie ; Tual, Séverine ; Bureau, Mathilde

RATIONALEFollowing the withdrawal of organochlorines and organophosphates, pyrethroids have become the most used insecticides in both agricultural and domestic settings.OBJECTIVESWe analyzed data from the French AGRICAN agricultural cohort to assess associations of occupational pyrethroid exposures and allergic/non-allergic asthma.METHODSAt enrollment, asthma diagnosed by a doctor was reported by 11 815 participants (7028 classified as non-allergic and 4458 as allergic based on the presence of eczema and/or hay fever). Individual exposures to 17 pyrethroids were defined in 124 992 participants, based on a combination of the history of pesticide treatment of 11 crops (grassland, vineyard, wheat/barley, corn, field peas, potatoes, tobacco, beets, sunflower, rape, fruits) and a crop-exposure matrix.MEASUREMENTS AND MAIN RESULTSIn men, no association was observed for any of the pyrethroids regardless of asthma phenotype. In contrast, in ever-exposed women, asthma risk was increased with use of any pyrethroid, both for allergic (+80 %) and non-allergic asthma (+40 %). Highest increases were observed for allergic asthma with fenpropathrin (OR = 2.00; 95 %CI:1.38-2.90), tralomethrin (OR = 1.81; 95 %CI:1.28-2.56), fenvalerate (OR = 1.81; 95 %CI:1.38-2.38), permethrin (OR = 1.78; 95 %CI:1.26-2.50) and deltamethrin (OR = 1.76; 95 %CI:1.35-2.29). Stratified analyses on women who reported living on a farm in early life showed stronger associations for non-allergic asthma. For women who reported early life living on vineyards associations with pyrethroids were stronger for both allergic and non-allergic asthma. Associations for women who lived on cattle farms were reduced for some pyrethroids.CONCLUSIONOccupational pyrethroid exposure was positively associated with both allergic and non-allergic asthma in women but not in men.

2025-05-01·ESMO Open

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial

Article

作者: Grenier, J ; Cameron, D ; Lemonnier, J ; Saint-Ghislain, M ; Legouffe, E ; Hardy-Bessard, A-C ; Kaluzinski, L ; Allouache, D ; Barthelemy, P ; Dalenc, F ; Bachelot, T ; Andre, F ; Bliss, J ; Martinez, M ; Brunt, M ; Mouret-Reynier, M-A ; Cottu, P ; Mailliez, A ; Canon, J-L ; Giacchetti, S ; Chabaud, S

BACKGROUNDThe randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses.PATIENTS AND METHODSWe randomly assigned 1278 patients in a 1 : 1 ratio to receive 2 years of placebo or everolimus, added to endocrine therapy for up to 4 years after initiation. Randomization was stratified by endocrine therapy agent, prior adjuvant versus neoadjuvant therapy, progesterone receptor expression, and lymph node involvement. Subgroup analyses by each stratification factor were pre-specified. Post hoc analyses were carried out according to menopausal status and age. Treatment adherence was also analyzed.RESULTSWe observed a limited trend toward more favorable prognostic features in tamoxifen-treated patients, with more frequent estrogen receptor-positive/progesterone receptor-positive tumors (88.5% versus 84.1%, P = 0.026) and less frequent pN2-positive status (39.8% versus 46.0%, P = 0.032). In premenopausal women, we observed a numerical benefit of everolimus: 3-year disease-free survival was 86% in the placebo group and 90% in the everolimus group (hazard ratio 0.76, 95% confidence interval 0.43-1.34). In premenopausal patients treated with tamoxifen (n = 153; 12.3%), we observed an even stronger trend in favor of everolimus as 3-year DFS was 84% in the placebo group and 91% in the everolimus group (hazard ratio 0.54, 95% confidence interval 0.28-1.02). Early discontinuation of either everolimus or placebo was less frequent in the tamoxifen group than in the aromatase inhibitor group: 48.0% versus 56.9% (P = 0.028).CONCLUSIONSThe present post hoc analyses generate hypotheses regarding the interaction between menopausal status, tamoxifen, and everolimus in patients with high-risk, ER-positive, human epidermal growth factor receptor type 2-negative early breast cancer. They suggest that tamoxifen alone is an underpowered endocrine treatment in high-risk premenopausal patients.

100 项与 Centre FranÃ§ois Baclesse 相关的药物交易

登录后查看更多信息

100 项与 Centre FranÃ§ois Baclesse 相关的转化医学

登录后查看更多信息